| Literature DB >> 36069785 |
Vanessa Peynenburg1, Heather Hadjistavropoulos1, David Thiessen1, Nickolai Titov2, Blake Dear2.
Abstract
BACKGROUND: Internet-delivered cognitive behavioral therapy (ICBT) can improve access to mental health care for students, although high attrition rates are concerning and little is known about long-term outcomes. Motivational interviewing (MI) exercises and booster lessons can improve engagement and outcomes in face-to-face cognitive behavioral therapy.Entities:
Keywords: boosters; internet-delivered cognitive behavioral therapy; motivational interviewing; postsecondary students; transdiagnostic
Mesh:
Year: 2022 PMID: 36069785 PMCID: PMC9494224 DOI: 10.2196/40637
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 7.076
Figure 1Patient flow from screening to the 3-month follow-up. ER: emergency room; MI: motivational interviewing.
Pretreatment demographic and clinical characteristics by group (N=277).
| Variable | All groups | Standard (n=71) | MIa (n=67) | Booster (n=71) | MI+booster (n=68) | ||||||
| Age (years), mean (SD; range) | 23.73 (5.95; 17-46) | 23.57 (6.11; 18-44) | 24.66 (6.58; 18-46) | 23.35 (5.86; 17-43) | 23.44 (5.28; 18-39) | ||||||
|
| |||||||||||
|
| Man | 45 (16.2) | 10 (14.1) | 6 (9.1) | 12 (18.2) | 17 (25) | |||||
|
| Woman | 224 (80.9) | 57 (80.3) | 58 (86.6) | 58 (81.7) | 51 (75) | |||||
|
| Nonbinary | 5 (1.8) | 2 (2.8) | 2 (3) | 1 (1.5) | 0 (0) | |||||
|
| Prefer not to disclose or not listed | 3 (1.1) | 2 (2.8) | 1 (1.5) | 0 (0) | 0 (0) | |||||
|
| |||||||||||
|
| Single or never married | 113 (41.5) | 31 (43.7) | 22 (33.3) | 31 (47) | 29 (42.6) | |||||
|
| Dating | 107 (38.6) | 26 (36.6) | 24 (35.8) | 29 (40.8) | 28 (41.2) | |||||
|
| Married or common law | 31 (11.4) | 8 (11.3) | 13 (19.7) | 5 (7.6) | 5 (7.4) | |||||
|
| Living with partner | 18 (6.4) | 4 (5.6) | 3 (4.5) | 5 (7.6) | 6 (8.8) | |||||
|
| Separated or divorced or widowed | 8 (3) | 2 (2.8) | 5 (7.6) | 1 (1.5) | 0 (0) | |||||
|
| Living with someone | 224 (80.9) | 55 (77.5) | 56 (83.6) | 57 (80.3) | 56 (82.4) | |||||
|
| |||||||||||
|
| University of Regina | 186 (67.1) | 47 (66.2) | 46 (70.1) | 47 (66.2) | 45 (66.2) | |||||
|
| University of Saskatchewan | 59 (21.3) | 14 19.7 () | 11 (16.4) | 18 (25.4) | 16 (23.5) | |||||
|
| Saskatchewan Polytechnic | 10 (3.6) | 1 (1.4) | 6 (9.1) | 1 (1.4) | 2 (2.9) | |||||
|
| Other | 22 (8.1) | 9 (12.7) | 3 (4.5) | 5 (7) | 5 (7.7) | |||||
|
| |||||||||||
|
| Full-time student | 235 (85.5) | 61 (87.1) | 53 (79.1) | 62 (87.3) | 59 (88.1) | |||||
|
| Part-time student | 40 (14.5) | 9 (12.9) | 14 (20.9) | 8 (12.7) | 8 (11.9) | |||||
|
| |||||||||||
|
| First-year undergraduate | 67 (24.6) | 19 (27.1) | 14 (21.2) | 21 (30.4) | 13 (19.4) | |||||
|
| Second-year undergraduate | 57 (21) | 13 (18.6) | 17 (25.8) | 8 (11.6) | 19 (28.4) | |||||
|
| Third-year undergraduate | 62 (22.8) | 18 (25.7) | 17 (25.8) | 16 (23.2) | 11 (16.4) | |||||
|
| Fourth-year undergraduate | 44 (16.2) | 10 (14.3) | 7 (10.6) | 15 (21.7) | 12 (17.9) | |||||
|
| Fifth or higher year undergraduate | 18 (6.6) | 3 (4.3) | 7 (10.6) | 4 (5.8) | 4 (6) | |||||
|
| Graduate or professional student | 26 (8.8) | 7 (10) | 4 (6.1) | 5 (7.2) | 8 (12) | |||||
| International student, n (%) | 10 (3.6) | 3 (4.3) | 2 (3) | 1 (1.4) | 4 (5.9) | ||||||
| English not the first language, n (%) | 24 (8.7) | 2 (2.8) | 5 (7.5) | 6 (8.6) | 11 (16.2) | ||||||
|
| |||||||||||
|
| Paid work | 135 (48.7) | 39 (54.9) | 32 (47.8) | 30 (44.1) | 30 (44.1) | |||||
|
| Unemployed | 142 (51.3) | 32 (45.1) | 35 (52.2) | 38 (55.9) | 38 (55.9) | |||||
|
| |||||||||||
|
| White | 201 (72.6) | 53 (74.6) | 49 (73.1) | 54 (76.1) | 45 (66.2) | |||||
|
| Indigenous | 20 (7.2) | 6 (8.5) | 8 (11.9) | 3 (4.2) | 3 (4.4) | |||||
|
| Asian | 26 (9.4) | 3 (4.2) | 4 (6) | 8 (11.2) | 11 (16.2) | |||||
|
| Other | 30 (10.8) | 9 (12.7) | 6 (9) | 6 (8.5) | 9 (13.2) | |||||
|
| |||||||||||
|
| Large city (>200,000) | 191 (69) | 49 (69) | 44 (65.7) | 52 (73.2) | 46 (67.6) | |||||
|
| Small to medium city | 23 (8.3) | 8 (11.3) | 6 (9) | 7 (9.9) | 2 (2.9) | |||||
|
| Small rural location (<10,000) | 63 (22.7) | 14 (19.7) | 17 (25.4) | 12 (16.9) | 20 (29.4) | |||||
|
| |||||||||||
|
| Physician or medical professional | 88 (31.9) | 19 (27.1) | 23 (34.3) | 22 (31) | 24 (35.3) | |||||
|
| Web-based source (eg, website or email) | 70 (25.4) | 19 (27.1) | 17 (25.4) | 20 (28.2) | 14 (20.6) | |||||
|
| Counseling services | 37 (13.4) | 10 (14.3) | 11 (16.4) | 6 (8.5) | 10 (14.7) | |||||
|
| Friend or family member or employer | 35 (12.7) | 6 (8.6) | 10 (14.9) | 12 (16.9) | 7 (10.3) | |||||
|
| Presentation | 12 (4.3) | 5 (7.1) | 2 (2.8) | 2 (2.8) | 3 (4.4) | |||||
|
| Printed poster or media | 4 (1.4) | 4 (5.7) | 0 (0) | 0 (0) | 1 (1.5) | |||||
|
| Other | 30 (10.9) | 7 (10) | 4 (6) | 9 (12.7) | 8 (11.8) | |||||
|
| |||||||||||
|
| Lifetime mental health service use | 158 (57) | 36 (50.7) | 47 (70.1) | 38 (53.5) | 37 (54.4) | |||||
|
| Lifetime hospitalization for mental health | 22 (7.9) | 3 (4.2) | 9 (13.4) | 7 (9.9) | 3 (4.4) | |||||
|
| Mental health diagnosis | 105 (37.9) | 27 (38) | 32 (47.8) | 27 (38) | 19 (27.7) | |||||
|
| Taking psychotropic medication in the past 3 months | 101 (36.5) | 20 (28.2) | 29 (43.3) | 23 (32.4) | 29 (42.6) | |||||
|
| Current mental health service use | 76 (27.4) | 19 (26.8) | 23 (34.3) | 12 (16.9) | 22 (32.4) | |||||
|
| Pretreatment GAD-7c ≥10 | 216 (78) | 58 (81.7) | 49 (73.1) | 55 (77.5) | 54 (79.4) | |||||
|
| Pretreatment PHQ-9d ≥10 | 213 (76.9) | 53 (74.6) | 52 (77.6) | 55 (77.5) | 53 (77.9) | |||||
|
| Pretreatment GAD-7 ≥10 and PHQ-9 ≥10 | 186 (67.1) | 48 (67.6) | 44 (65.7) | 47 (66.2) | 47 (69.1) | |||||
|
| No clinical scores | 34 (12.3) | 8 (11.3) | 10 (14.9) | 8 (11.3) | 8 (11.8) | |||||
|
| |||||||||||
|
| CEQe | 21.16 (4.19) | 20.63 (3.98) | 21.91 (4.09) | 20.90 (4.61) | 21.34 (4.09) | |||||
|
| CQ-3f | 24.05 (4.22) | 24.29 (3.64) | 23.39 (4.51) | 24.20 (4.46) | 24.35 (4.41) | |||||
aMI: motivational interviewing.
bLocation is based on where the client was residing at intake.
cGAD-7: 7-item Generalized Anxiety Disorder.
dPHQ-9: 9-item Patient Health Questionnaire.
eCEQ: Credibility and Expectancy Questionnaire.
fCQ-3: 3-item Change Questionnaire.
Estimated marginal means, 95% CIs, percentage changes, and effect sizes (Cohen dd) for primary and secondary outcomes by factor (MIa and booster) using pooled imputations.
| Outcomes | Estimated marginal means, (SD) | Changes from pretreatment (%), 95% CI | Within-group effect sizes from pretreatment, 95% CI | |||||||||||||||||||||
|
| Pretreatment | Posttreatment | 1 month | 3 months | To posttreatment | To 1 month | To 3 months | To posttreatment | To 1 month | To 3 months | ||||||||||||||
|
| ||||||||||||||||||||||||
|
|
| |||||||||||||||||||||||
|
|
| MI | 14.24 (5.56) | 6.90 (4.24) | 7.04 (4.92) | 7.41 (4.78) | 52 (46 to 57) | 51 (44 to 57) | 48 (42 to 54) | 1.48 (1.21 to 1.75) | 1.37 (1.10 to 1.63) | 1.31 (1.05 to 1.58) | ||||||||||||
|
|
| No MI | 14.72 (5.97) | 7.91 (4.54) | 7.73 (5.01) | 7.79 (5.31) | 46 (41 to 52) | 48 (41 to 54) | 47 (41 to 53) | 1.28 (1.02 to 1.54) | 1.27 (1.01 to 1.52) | 1.22 (0.97 to 1.48) | ||||||||||||
|
|
| Booster | 14.16 (5.16) | 7.77 (4.41) | 7.60 (5.00) | 7.59 (4.78) | 45 (40 to 51) | 46 (40 to 53) | 46 (40 to 53) | 1.33 (1.07 to 1.59) | 1.29 (1.03 to 1.55) | 1.32 (1.06 to 1.58) | ||||||||||||
|
|
| No booster | 14.80 (6.33) | 7.03 (4.41) | 7.16 (4.95) | 7.60 (5.33) | 53 (47 to 58) | 52 (45 to 58) | 49 (42 to 55) | 1.42 (1.16 to 1.69) | 1.34 (1.08 to 1.60) | 1.23 (0.97 to 1.48) | ||||||||||||
|
|
| |||||||||||||||||||||||
|
|
| MI | 13.51 (4.71) | 6.10 (3.89) | 6.78 (4.75) | 7.17 (5.42) | 55 (50 to 60) | 50 (43 to 56) | 47 (40 to 54) | 1.71 (1.43 to 1.99) | 1.42 (1.15 to 1.69) | 1.25 (0.98 to 1.51) | ||||||||||||
|
|
| No MI | 13.88 (4.82) | 7.14 (4.28) | 7.11 (4.94) | 7.51 (5.33) | 49 (43 to 54) | 49 (42 to 55) | 46 (39 to 53) | 1.47 (1.21 to 1.74) | 1.38 (1.12 to 1.64) | 1.25 (1.00 to 1.50) | ||||||||||||
|
|
| Booster | 13.66 (4.75) | 7.12 (4.19) | 7.34 (5.00) | 7.59 (5.42) | 48 (42 to 54) | 46 (40 to 53) | 44 (37 to 52) | 1.46 (1.19 to 1.72) | 1.29 (1.04 to 1.55) | 1.19 (0.93 to 1.44) | ||||||||||||
|
|
| No booster | 13.73 (4.80) | 6.12 (4.00) | 6.57 (4.68) | 7.10 (5.32) | 55 (50 to 60) | 52 (46 to 58) | 48 (41 to 55) | 1.72 (1.44 to 1.99) | 1.51 (1.24 to 1.77) | 1.31 (1.05 to 1.57) | ||||||||||||
|
|
| |||||||||||||||||||||||
|
|
| MI | 17.47 (6.27) | 19.63 (7.30) | 20.14 (6.73) | 19.76 (7.62) | 17 (7 to 28) | 21 (11 to 32) | 18 (7 to 30) | 0.32 (0.08, 0.56) | 0.41 (0.17 to 0.65) | 0.33 (0.09 to 0.57) | ||||||||||||
|
|
| No MI | 17.24 (6.67) | 19.24 (7.33) | 20.38 (6.09) | 19.12 (7.44) | 16 (5 to 27) | 25 (15 to 34) | 15 (4 to 26) | 0.28 (0.05 to 0.52) | 0.49 (0.25 to 0.73) | 0.27 (0.03 to 0.50) | ||||||||||||
|
|
| Booster | 17.29 (6.75) | 19.81 (6.94) | 20.52 (6.37) | 19.41 (7.36) | 20 (9 to 31) | 25 (16 to 35) | 17 (6 to 28) | 0.37 (0.13 to 0.61) | 0.49 (0.25 to 0.73) | 0.30 (0.06 to 0.54) | ||||||||||||
|
|
| No booster | 17.43 (6.19) | 19.05 (7.65) | 19.99 (6.45) | 19.48 (7.71) | 13 (2 to 24) | 20 (10 to 31) | 16 (5 to 28) | 0.23 (–0.01 to 0.47) | 0.40 (0.17 to 0.64) | 0.29 (0.06 to 0.53) | ||||||||||||
|
| ||||||||||||||||||||||||
|
|
| |||||||||||||||||||||||
|
|
| MI | 19.28 (6.70) | 13.19 (6.79) | 11.99 (7.27) | 12.37 (7.46) | 32 (25 to 38) | 38 (31 to 45) | 36 (29 to 43) | 0.90 (0.65 to 1.15) | 1.04 (0.79 to 1.30) | 0.97 (0.72 to 1.22) | ||||||||||||
|
|
| No MI | 20.06 (5.75) | 15.63 (7.00) | 12.54 (7.09) | 12.24 (7.38) | 22 (16 to 28) | 37 (31 to 44) | 39 (32 to 46) | 0.69 (0.45 to 0.93) | 1.16 (0.91 to 1.41) | 1.18 (0.93 to 1.43) | ||||||||||||
|
|
| Booster | 19.58 (6.22) | 14.52 (6.53) | 12.27 (7.25) | 12.18 (7.13) | 26 (19 to 32) | 37 (30 to 44) | 38 (31 to 45) | 0.79 (0.55 to 1.03) | 1.08 (0.83 to 1.33) | 1.10 (0.85 to 1.35) | ||||||||||||
|
|
| No booster | 19.76 (6.26) | 14.20 (7.45) | 12.25 (7.12) | 12.43 (7.70) | 28 (21 to 35) | 38 (31 to 45) | 37 (30 to 44) | 0.81 (0.56 to 1.05) | 1.12 (0.86 to 1.37) | 1.04 (0.79 to 1.29) | ||||||||||||
|
|
| |||||||||||||||||||||||
|
|
| MI | 4.59 (4.86) | 3.08 (3.95) | —g | — | 33 (18 to 48) | — | — | 0.34 (0.10 to 0.58) | — | — | ||||||||||||
|
|
| No MI | 4.29 (4.06) | 3.52 (3.90) | — | — | 18 (2 to 34) | — | — | 0.19 (–0.04 to 0.43) | — | — | ||||||||||||
|
|
| Booster | 4.30 (4.28) | 3.28 (3.86) | — | — | 24 (7 to 40) | — | — | 0.25 (0.01 to 0.48) | — | — | ||||||||||||
|
|
| No booster | 4.58 (4.65) | 3.32 (4.00) | — | — | 28 (12 to 43) | — | — | 0.29 (0.05 to 0.53) | — | — | ||||||||||||
|
|
| |||||||||||||||||||||||
|
|
| MI | 2.32 (5.10) | 1.95 (4.72) | — | — | 16 (20 to 52) | — | — | 0.07 (–0.16 to 0.31) | — | — | ||||||||||||
|
|
| No MI | 2.90 (6.04) | 2.36 (5.21) | — | — | 19 (–12 to 49) | — | — | 0.10 (–0.14 to 0.33) | — | — | ||||||||||||
|
|
| Booster | 2.52 (5.09) | 1.66 (3.65) | — | — | 34 (8 to 60) | — | — | 0.19 (–0.04 to 0.43) | — | — | ||||||||||||
|
|
| No booster | 2.70 (6.09) | 2.66 (6.00) | — | — | 2 (–36 to 40) | — | — | 0.01 (–0.23 to 0.24) | — | — | ||||||||||||
aMI: motivational interviewing.
bPHQ-9: 9-item Patient Health Questionnaire.
cGAD-7: 7-item Generalized Anxiety Disorder.
dPAF: Perceptions of Academic Functioning.
eSDS: Sheehan Disability Scale.
fAUDIT: Alcohol Use Disorder Identification Test.
gThe AUDIT and DUDIT were only administered before treatment and after treatment; thus, data are not available for the percentage change and effect sizes at the 1-month and 3-month follow-ups.
hDUDIT: Drug Use Disorder Identification Test.
Between groups effect sizes (Cohen d) for primary and secondary outcomes based on MIa and booster factors using pooled imputations.
| Outcomes | After treatment, Cohen | 1-month follow-up, Cohen | 3-month follow-up, Cohen | |||||
|
| ||||||||
|
|
| |||||||
|
|
| PHQ-9b | 0.23 (−0.01 to 0.47) | 0.14 (−0.10 to 0.37) | 0.08 (−0.16 to 0.31) | |||
|
|
| GAD-7c | 0.25 (0.02 to 0.49) | 0.07 (−0.17 to 0.30) | 0.06 (−0.17 to 0.30) | |||
|
|
| PAFd | 0.05 (−0.18 to 0.29) | −0.04 (−0.27 to 0.20) | 0.09 (−0.15 to 0.32) | |||
|
|
| |||||||
|
|
| SDSe | 0.35 (0.12 to 0.59) | 0.08 (−0.16 to 0.31) | −0.02 (−0.25 to 0.22) | |||
|
|
| AUDITf | 0.11 (−0.12 to 0.35) | —g | — | |||
|
|
| DUDITh | 0.08 (−0.15 to 0.32) | — | — | |||
|
| ||||||||
|
|
| |||||||
|
|
| PHQ-9 | −0.17 (−0.40 to 0.07) | −0.09 (−0.32 to 0.15) | 0.00 (−0.23 to 0.24) | |||
|
|
| GAD-7 | −0.24 (−0.48 to −0.01) | −0.16 (−0.39 to 0.08) | −0.09 (−0.33 to 0.14) | |||
|
|
| PAF | 0.10 (−0.13 to 0.34) | 0.08 (−0.15 to 0.32) | −0.01 (−0.25 to 0.23) | |||
|
|
| |||||||
|
|
| SDS | −0.05 (−0.28 to 0.19) | 0.00 (−0.24 to 0.23) | 0.03 (−0.20 to 0.27) | |||
|
|
| AUDIT | 0.00 (−0.23 to 0.24) | — | — | |||
|
|
| DUDIT | 0.20 (−0.03 to 0.44) | — | — | |||
aMI: motivational interviewing.
bPHQ-9: 9-item Patient Health Questionnaire.
cGAD-7: 7-item Generalized Anxiety Disorder.
dPAF: Perceptions of Academic Functioning.
eSDS: Sheehan Disability Scale.
fAUDIT: Alcohol Use Disorder Identification Test.
gThe AUDIT and DUDIT were only administered before treatment and after treatment; thus, data are not available for the percentage change and effect sizes at the 1-month and 3-month follow-ups.
hDUDIT: Drug Use Disorder Identification Test.